Enrollment has begun in an early stage coronavirus vaccine trial utilizing Dynavax's technology.
News & Analysis: Dynavax Technologies
This stock has the potential to break new highs with its key hepatitis B vaccine and emerging vaccine-adjuvant platform for COVID-19 vaccines.
Pfizer released intriguing data regarding its own COVID-19 vaccine.
Bad news about rising COVID-19 cases is good news for these stocks.
Higher numbers of COVID-19 cases helped these biotechs, which are working on treatments and vaccines for the disease.
An early-stage clinical study has begun evaluating a COVID-19 vaccine candidate that features Dynavax's adjuvant.
One is developing a COVID-19 vaccine; the other two are from rebounding industries.
Last week's momentum continued for the high-flying biotech stock.
The company's vaccine partner made positive comments about its progress today.
Dynavax's COVID-19 vaccine program is turning heads this morning.